Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1439A versus Atripla in treatment-naive HIV-1 infection
NL-OMON42331Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Delstrigo in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Virologic response at Week 48 and Neuropsychiatric adverse events by Week 48. Planned start Jun 2015; status: withdrawn.
02
Drugs
Delstrigo
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON42331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42331.